The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.

Licensing 52

Licensing Licensing Medicine Development 52

pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus alliance with UK biotech Artios Pharma to develop precision medicines for cancer. billion along with its developer Advanced Accelerator Applications in 2017. The drug made $445 million in sales last year.

DNA 52

DNA Licensing Licensing Gene Therapy 52

The Pharma Data

MARCH 16, 2021

AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19. Financial considerations.

Antibody 52

Antibody Trials Radiology Development 52

The Pharma Data

APRIL 15, 2022

The test is performed by a qualified, trained operator under the supervision of a health care provider licensed or authorized by state law to prescribe tests and can provide results in less than three minutes. director of the FDA’s Center for Devices and Radiological Health. for the next public health emergency.”. “The

Radiology 52

Radiology Cosmetics Production Licensing 52

The Pharma Data

NOVEMBER 9, 2021

Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. “ Molnupiravir is being developed by Merck &Co.,Inc. Since certified by Ridgeback, all finances used for the development of molnupiravir have been handed by Merck and by Wayne and Wendy Holman of Ridgeback. With these exercised options, theU.S.

Medicine 52

Medicine Radiology Development Drugs 52

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. W911QY-21-9-0001.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

MARCH 25, 2022

” Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “Today’s positive CHMP recommendation represents a significant step forward in our ongoing efforts to introduce additional, important preventative measures for people in Europe at higher risk of developing COVID-19. W911QY-21-9-0001.

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

The Pharma Data

JUNE 25, 2021

In the overall trial population, AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% (95% confidence interval (CI): -26, 65) compared to placebo, which was not statistically significant (Table 1). AZD7442 is being assessed in both IM and intravenous administration routes. W911QY-21-9-0001.

Trials 52

Trials Antibody In-Vitro Medicine 52

The Pharma Data

AUGUST 22, 2021

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(7) and were optimised by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. W911QY-21-9-0001. About AstraZeneca.

Trials 52

Trials Antibody Vaccination Vaccine 52

XTalks

JUNE 12, 2023

These powerhouse organizations have not only distinguished themselves through their cutting-edge devices and technologies but also via their robust research and development (R&D) capabilities, unwavering commitment to quality and extensive global reach. The company reported an investment of $2.7

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

pharmaphorum

SEPTEMBER 30, 2022

There will still be much debate about the exact license granted to the drug and cost-effectiveness deliberations, according to Prof Passmore. We need to develop an effective and quick triage system so we can reassure people without Alzheimer’s and offer treatment to those with Alzheimer’s.”

Clinical Trials 52

Clinical Trials Clinical Trials Sales Drugs 52

The Pharma Data

DECEMBER 23, 2020

Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA). It will be funded by the U.S. Department of Defense.

DNA 40

DNA Vaccination Vaccine Immune Response 40

FDA Law Blog

DECEMBER 11, 2023

FDA’s assumption that 50% of the tests will be exempt is particularly baffling because the laboratories are ones licensed to perform high complexity tests. During COVID-19, however, FDA essentially stopped reviewing pre‑submissions severely limiting feedback to non-COVID test developers. 1] [link] [2] U.S. 4] PRIA at 28. [5]

In-Vitro 69

In-Vitro Regulation Production Development 69

The Pharma Data

AUGUST 5, 2021

Presenting the company’s half-year financial report, he highlighted how “we have achieved major successes in developing and launching drugs, some of which have blockbuster potential. The platform already has potentially ground-breaking medical innovations in clinical development, such as a therapy for the treatment of Parkinson’s.

Sales 52

Sales Production Gene Therapy Allergies 52